XT
XERS icon

XTX Topco’s Xeris Biopharma Holdings XERS Stock Holding History

XTX Topco’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
43,190
+22,918
+113% +$146K ﹤0.01% 2793
2026
Q1 		$118K Buy
+20,272
New +$134K ﹤0.01% 3055
2025
Q3 		– Sell
-24,662
Closed -$115K – 3386
2025
Q2 		$115K Sell
24,662
-191,566
-89% -$878K ﹤0.01% 1856
2025
Q1 		$1.19M Buy
+216,228
New +$873K 0.06% 459
2024
Q4 		– Sell
-13,890
Closed -$39.6K – 3011
2024
Q3 		$39.6K Sell
13,890
-17,892
-56% -$46K ﹤0.01% 1728
2024
Q2 		$71.5K Sell
31,782
-223,267
-88% -$450K 0.01% 1467
2024
Q1 		$564K Buy
255,049
+238,563
+1,447% +$617K 0.08% 423
2023
Q4 		$38.7K Buy
+16,486
New +$30.4K 0.01% 1276
2023
Q2 		– Sell
-233,385
Closed -$380K – 1905
2023
Q1 		$380K Buy
233,385
+44,474
+24% +$55.7K 0.08% 474
2022
Q4 		$251K Buy
+188,911
New +$267K 0.05% 701
2021
Q2 		– Sell
-10,596
Closed -$48K – 1132
2021
Q1 		$48K Buy
+10,596
New +$57.1K 0.02% 625

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

XTX Topco's XERS Position: Q2 2026 in Review

XTX Topco increased its Xeris Biopharma Holdings (XERS) stake by 113% in Q2 2026, buying an estimated $146K and bringing the position to 43,190 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

XTX Topco first reported a position in XERS in Q1 2021 and has held it in 11 quarters since. The position peaked at $1.19M in Q1 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • XTX Topco held 43,190 shares of Xeris Biopharma Holdings worth $342K as of Q2 2026.
  • XTX Topco bought 22,918 Xeris Biopharma Holdings shares in Q2 2026, an estimated $146K.
  • Xeris Biopharma Holdings made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #2793 holding.
  • XTX Topco first reported a position in Xeris Biopharma Holdings in Q1 2021 and has held it in 11 quarters since.
  • XTX Topco's Xeris Biopharma Holdings position peaked at $1.19M in Q1 2025.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.